Showing results (211-220 of 240) with videos related to

Sort By:
Pageof 24
British Journal of Haematology|February 9, 2022
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL studyElena Maria Elli, Ambra Di Veroli, Daniela Bartoletti, et al.
Annals of Hematology|January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapyFrancesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Cancer Medicine|October 29, 2019
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysisEnrico Balleari, Rosa Angela Filiberti, Chiara Salvetti, et al.
Cancer|March 19, 2021
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practiceMarino Clavio, Elena Crisà, Maurizio Miglino, et al.
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
The New England Journal of Medicine|December 11, 2012
Cardiovascular events and intensity of treatment in polycythemia veraRoberto Marchioli, Guido Finazzi, Giorgina Specchia, et al.
Cancer|August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Annals of Hematology|July 5, 2014
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trialMariam G Aslanyan, Leonie I Kroeze, Saskia M C Langemeijer, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Cancer|April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosisFrancesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
Pageof 24